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ABSTRACT
Rapamycin analogues have antitumor efficacy in several tumor types, however 
few patients demonstrate tumor regression. Thus, there is a pressing need for markers 
of intrinsic response/resistance and rational combination therapies. We hypothesized 
that epithelial-to-mesenchymal transition (EMT) confers rapamycin resistance. We 
found that the epithelial marker E-cadherin protein is higher in rapamycin sensitive 
(RS) cells and mesenchymal breast cancer cell lines selected by transcriptional EMT 
signatures are less sensitive to rapamycin. MCF7 cells, transfected with constitutively 
active mutant Snail, had increased rapamycin resistance (RR) compared to cells 
transfected with wild-type Snail. Conversely, we transfected two RR mesenchymal 
cell lines—ACHN and MDA-MB-231—with miR-200b/c or ZEB1 siRNA to promote 
mesenchymal-to-epithelial transition. This induced E-cadherin expression in both 
cell lines, and ACHN demonstrated a significant increase in RS. Treatment of ACHN 
and MDA-MB-231 with trametinib modulated EMT in ACHN cells in vitro. Treatment 
of MDA-MB-231 and ACHN xenografts with trametinib in combination with rapamycin 
resulted in significant growth inhibition in both but without an apparent effect on EMT. 
Future studies are needed to determine whether EMT status is predictive of sensitivity 
to rapalogs and to determine whether combination therapy with EMT modulating 
agents can enhance antitumor effects of PI3K/mTOR inhibitors.
INTRODUCTION
The PI3K/mTOR pathway performs essential 
functions for maintaining the malignant phenotype 
including controlling cell growth, metabolism, and 
autophagy [1, 2]. Rapamycin and its analogs are allosteric 
mTOR inhibitors that bind FKBP12 and mTOR, and 
predominantly inhibit mTORC1. The rapamycin 
analog temsirolimus is approved by the Food and Drug 
Administration for the treatment of advanced renal cell 
carcinoma and the rapamycin analog everolimus is FDA-
approved for the treatment of pancreatic neuroendocrine 
tumors, renal cell carcinoma, sub-ependymal giant cell 
astrocytoma associated with tuberous sclerosis, and the 
treatment of hormone-receptor positive breast cancer (in 
combination with exemestane). However, rapalogs have 
shown objective responses in only a minority of patients. 
Mechanisms of intrinsic sensitivity and resistance to 
rapalogs remain largely unknown.
The epithelial to mesenchymal transition (EMT) is 
defined by the loss of intracellular links along with the gain 
of migratory and invasive abilities [3]. Plasticity exists within 
this process, allowing cells to transition from epithelial to 
mesenchymal and then resume an epithelial phenotype [4]. 
Snail and ZEB transcription factors are known EMT drivers, 
through inducing the crucial step of loss of cell polarity; their 
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expression correlates with time to recurrence and survival 
in patients with breast carcinoma [3, 5]. Cell lines without 
E-cadherin expression or with mutations in E-cadherin 
have increased tumorigenicity and metastasis in mice 
[6–9]. Conversely, miR-200 has been shown to decrease 
the expression of ZEB transcription factors to maintain the 
epithelial phenotype [3, 10–14]. Forced expression of miR-
200c restores the chemotherapeutic sensitivity of breast 
cancer cells [15], while loss of miR-200 correlates with 
increased vimentin expression and decreased E-cadherin 
expression in breast cancer cells [11, 13, 14].
Type 3 EMT is involved in cancer progression 
and metastasis, and thus it is a potential mechanism of 
attaining the malignant phenotype [4]. This phenotype is 
achieved through other common cancer signaling networks 
including MAPK, PI3K, and Smad [3]. MEK inhibitors, 
which target the MAPK pathway, have previously been 
shown to decrease vimentin expression and invasion in the 
triple negative breast cancer cell line MDA-MB-231 [16]. 
Trametinib (GSK1120212) is an orally bioavailable 
selective allosteric MEK1/MEK2 inhibitor that has 
been approved by the Food and Drug Administration 
(FDA) for treatment of BRAF V600 mutant melanoma 
in combination with dabrafenib and that is effective for 
inhibiting growth in triple negative breast cancer cell lines 
in vitro [17]. Histone deacetylase (HDAC) inhibitors, a 
class of antitumor agents, reverse EMT. Vorinostat, an 
FDA approved drug for the treatment of cutaneous T-cell 
lymphoma, is an inhibitor in this group that induces 
E-cadherin and inhibits vimentin expression [18].
Despite the cross-talk between EMT programming 
and the mTOR pathway, the relationship between 
rapamycin sensitivity in immortalized cancer cells lines 
and markers of EMT has not been previously investigated. 
We performed a functional proteomic screen with reverse 
phase protein array (RPPA) to determine biomarkers 
associated with sensitivity and resistance to rapamycin, 
and we found and association with EMT and rapamycin 
resistance. We hypothesized that the mesenchymal status 
of cancer cells imparts resistance to rapamycin. Thus, 
we proposed to modulate EMT in immortalized cancer 
cell lines and determine whether alterations in EMT 
biomarkers correlated with sensitivity to rapamycin both 
in vitro and in mouse xenografts.
RESULTS
Rapamycin sensitivity correlates with EMT 
status in vitro
To determine sensitivity to rapamycin in 
immortalized cancer cell lines, sulforhodamine B (SRB) 
assay was performed to classify cell lines as resistant or 
sensitive. Twelve cell lines with an IC50 of rapamycin 
greater than 100 nM were classified as resistant 
and 31 with IC50s less than 100 nM as sensitive [19]. 
Reverse phase protein arrays were used to compare the 
functional proteomics profiles. We assessed whether EMT 
markers are differentially expressed in rapamycin sensitive 
(RS) compared to resistant (RR) immortalized cell lines. 
RS cell lines demonstrated increased expression of 
epithelial marker E-cadherin while RR cell lines showed 
increased expression of mesenchymal marker Smad3 
(Figure 1A). To validate these findings, western blotting 
for markers of EMT was performed in selected RR and RS 
cell lines. E-cadherin expression differentiated cell lines 
sensitive to rapamycin from those resistant to rapamycin, 
which expressed vimentin (Figure 1B). Thus, RS cell lines 
tended to display epithelial markers while RR cell lines 
exhibited mesenchymal markers.
Transcriptional signatures of EMT are being 
pursued as a predictor of response/sensitivity to selected 
therapies. We sought to determine whether transcriptional 
signature of EMT is associated with rapamycin sensitivity. 
Daemen et al. recently studied a panel of breast cancer 
cell lines and shared their gene expression profiles as well 
as sensitivity to experimental or approved therapeutic 
agents including rapamycin, as well a rapalogs everolimus 
and temsirolimus [20]. We classified these breast cancer 
cell lines as epithelial or mesenchymal based on their 
transcriptional profiles using genes within the EMT 
signature described by Byers et al. as a classifier [21]. 
Based on 2-way hierarchical clustering, 11 cell lines 
were clustered into the mesenchymal group (red bar) and 
40 were clustered into the epithelial (green bar) group 
(Figure 2A). The ranks and the median of Log10GI50 of 
rapamycin were significantly lower in the epithelial group 
than the mesenchymal group (  p = 0.004, Figure 2B). 
The median Log10GI50 of everolimus was lower in the 
epithelial group than the mesenchymal group ( p = 0.096). 
The median Log10GI50 of temsirolimus was lower in 
the epithelial group than the mesenchymal group, but 
this difference did not achieve statistical significance. 
We also classified the breast cancer cell lines with 261 
probe sets mapping to the 125 gene symbols of a EMT 
signature described Gröger et al. [22]. Based on 2-way 
hierarchical clustering, the classification of cell lines 
with this signature was very similar with 10 cell lines 
clustered as mesenchymal and 41 clustered as epithelial; 
HCC1569 was classified into the mesenchymal group by 
Byers’ signature but epithelial group by Gröger’s signature 
(Supplementary Figure 1). The median Log10GI50 of 
rapamycin was significantly lower in the epithelial group 
than that in the mesenchymal group with this classification 
as well (  p = 0.004; Supplementary Figure 2).
Induction of EMT alters Erk phosphorylation 
and decreases rapamycin sensitivity
To explore this correlation between rapamycin 
sensitivity and EMT further, we sought to modulate 
EMT and then study the effect on rapamycin sensitivity 
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and mTOR signaling. To modulate EMT status in a 
stable manner, the epithelial breast carcinoma cell line, 
MCF7, had previously been transfected with a wild-type 
Snail (Snail-WT), and two mutant Snails (Snail-2SA and 
Snail-6SA) [23]. Snail-2SA is resistant to degradation by 
GSK-3β. Snail-6SA variant is also stable and a potent 
inducer of EMT in MCF7 cells. Western blotting for 
Snail, E-cadherin, and vimentin expression confirmed 
previous findings that MCF7 transfected with Snail-6SA 
mutant resulted in loss of E-cadherin expression and 
gain of vimentin expression (Figure 3A). The expression 
and phosphorylation of MAPK and Akt/mTOR pathway 
markers showed differences between MCF7 Snail-WT 
and Snail-6SA variants (Figure 3B). In Snail-6SA, 
rapamycin did not completely inhibit S6 phosphorylation. 
There was an increase in Akt phosphorylation but a 
decrease in total Akt expression. Total MEK expression 
was increased, which was accompanied by an increase 
in phospho-MEK (p-MEK). Contrary to this finding, Erk 
phosphorylation was decreased. In both Snail-WT and 
-6SA variants, rapamycin increased Erk phosphorylation, 
more significantly in Snail-6SA. To test the hypothesis 
that induction of EMT decreases sensitivity to rapamycin, 
MCF7 Snail-WT and MCF7 Snail-6SA were treated 
with varied doses of rapamycin. SRB assay exhibited 
statistically significant decrease in growth inhibition in 
MCF7 Snail-6SA at doses of rapamycin 0.01–1000 nM 
compared to MCF7 Snail-WT (Figure 3C). Induction of 
Figure 1: Rapamycin sensitive cell lines have increased E-cadherin expression compared to rapamycin resistant cell 
lines. A. Forty three cell lines, with known rapamycin IC50 values, were treated with vehicle or increasing doses of rapamycin for 2,  
24 or 72 hours in triplicates. Specific EMT markers were differentially expressed in RS compared to RR immortalized cell lines by RPPA. 
B. Western blotting assessed baseline expression of EMT markers in a panel of RS and RR cell lines.
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EMT in MCF7 resulted in increased baseline Erk 
phosphorylation, which was not regulated by rapamycin, 
and decreased sensitivity to rapamycin at higher doses, 
supporting our hypothesis that acquisition of mesenchymal 
markers and loss of epithelial markers imparts resistance 
to rapamycin.
Modulation of EMT Increases Rapamycin 
Sensitivity in ACHN In Vitro
To test whether modulation of EMT to a more 
epithelial phenotype could increase rapamycin sensitivity 
in RR mesenchymal cell lines, we targeted the EMT 
program through transfection of miR-200b/c mimics and 
siRNA knockdown of ZEB1. We selected to attempt EMT 
modulation in two RR cell lines: the triple-negative breast 
carcinoma cell line, MDA-MB-231, and the renal cell 
carcinoma cell line, ACHN.
Both cell lines demonstrated increased E-cadherin 
expression with miR-200b/c transfection (Figure 4A). 
Despite increased E-cadherin expression in MDA-
MB-231, there was no change in rapamycin sensitivity 
by SRB assay (data not shown). However, ACHN had 
increased sensitivity to rapamycin compared to control 
at all doses tested following miR-200b/c transfection, 
transforming from a RR to a RS cell line (Figure 4B).
Figure 2: Sensitivity to rapamycin and analogs in epithelial and mesenchymal cell lines. A. Breast cancer cell lines were 
grouped into epithelial (green bar) and mesenchymal (red bar) based on the Byers’ EMT signature. Each row represents a gene, and 
each column a cell line. B. Wilcoxon rank sum test was performed to compare the Log10GI50 values between epithelial and mesenchymal 
cell lines.
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Similarly, siRNA against ZEB1 was successful 
in abolishing ZEB1 expression in both ACHN and 
MDA-MB-231 compared to non-targeting siRNA, with 
concurrent increased expression of E-cadherin in both cell 
lines (Figure 4C). Similar to the miR-200b/c transfection, 
ZEB1 siRNA knockdown of MDA-MB-231 did not 
result in increased sensitivity to rapamycin compared to 
control (data not shown). However, ACHN demonstrated 
increased sensitivity to rapamycin 0.1–1000 nM following 
ZEB1 siRNA knockdown—once again converting from a 
RR to a RS cell line (Figure 4D).
Therefore, miR-200b/c transfection and ZEB1 
siRNA knockdown modulated EMT in both ACHN and 
MDA-MB-231 but only increased the sensitivity of ACHN 
to rapamycin.
HDAC inhibition modulates EMT and 
rapamycin sensitivity in vitro
As histone deacetylase (HDAC) inhibitors, have 
been reported to reverse EMT [18, 24], we determined 
if vorinostat reversed EMT in rapamycin resistant cell 
lines ACHN and MDA-MB-231. Treatment of these cell 
lines with vorinostat indeed increased E-cadherin levels 
(Figure 5A), demonstrating reversion of EMT. Increasing 
vorinostat dose did not increase E-cadherin expression 
(Supplementary Figure 3). The combination of rapamycin 
and vorinostat was strongly synergistic in ACHN at all 
concentrations and synergistic in MDA-MB-231 at lower 
concentrations (Figure 5B). To determine if vorinostat 
increased sensitivity to rapamycin in vivo, vorinostat 
alone or in combination with rapamycin was administered 
to MDA-MB-231 xenograft bearing mice for 38 days. 
Although the tumor volume in combination treatment group 
was slightly smaller than the single drug groups, there was 
no significant difference among the groups (Figure 5C). 
Notably, when expression of E-cadherin in MDA-MB-231 
xenografts was analyzed by RPPA, there was no significant 
increase in E-Cadherin with treatment. To the contrary, 
there was a statistically significant decrease in E-Cadherin 
with vorinostat treatment (  p = 0.0003); therefore vorinostat 
appeared to be unable to reverse EMT in vivo in this model.
In addition, vorinostat alone or in combination with 
two different doses of rapamycin was administered to 
Figure 3: MCF7 Snail-6SA has increased Erk phosphorylation and decreased sensitivity to higher doses of rapamycin.  
A. Snail, E-cadherin and vimentin expression was assessed in stably transfected MCF7 snail wild-type (Sn-WT) and MCF7 snail mutant 
(Sn-2SA and Sn-6SA) cell lines by western blotting. B. MCF7 snail wild-type (Snail-WT) and mutant (Snail-6SA) cell lines were treated 
with DMSO 0.1% or rapamycin 100 nM daily for 3 days. EMT, MAPK and mTOR pathway markers were assessed by western blotting.  
C. Rapamycin sensitivity in MCF7 snail wild-type (Snail-WT) or mutant (Snail-6SA) cell lines were assessed by SRB assay following  
96-hour treatment with increasing doses of rapamycin. **p < 0.01. Experiments were performed three times in triplicates and a representative 
set of results is displayed.
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ACHN bearing mice for 19 days. Compared to control, 
mean tumor volume decreased only in rapamycin 4 mg/kg 
group and was smaller in combination groups. There was 
no statistically significant difference among groups.
MEK inhibition modulates EMT in vitro and 
the combination of MEK and mTOR inhibition 
enhances antitumor efficacy in ACHN models  
in vivo
Previous studies have reported that MEK inhibition 
modulates EMT [16]. We thus tested whether the MEK 
inhibitor trametinib modulates EMT in ACHN and MDA-
MB-231 cell lines. Trametinib inhibited MEK signaling 
without a significant decrease in vimentin or increase 
in E-cadherin in MDA-MB-231 cells (Figure 6A). 
In contrast, in ACHN cells, trametinib demonstrated 
an increase in E-cadherin levels, demonstrating some 
reversion of EMT. Also of interest is that in ACHN 
cells, rapamycin only partially abrogated ribosomal 
S6 phosphorylation. Although trametinib alone did not 
modulate ribosomal S6 phosphorylation, trametinib added 
to rapamycin completely inhibited S6 phosphorylation.
To determine if MEK inhibition increases sensitivity 
to rapamycin in vivo, effects of the combination of 
trametinib and rapamycin compared to single agent 
therapy was tested. Trametinib alone or in combination 
with rapamycin for 14 days caused tumor regression 
in MDA-MB-231 xenografts (Figure 6B), but the 
combination with rapamycin did not cause greater tumor 
regression than trametinib alone. Percent change in tumor 
volume from initiation of treatment (Day 0) was compared 
Figure 4: miR-200b/c transfection and ZEB1 siRNA knockdown modulated EMT in ACHN and MDA-MB-231 but 
increased sensitivity to rapamycin only in ACHN. A. ACHN and MDA-MB-231 were transfected with miR-200b/c (+) and 
72 hours later cells were harvested. EMT markers were assessed by western blotting. B. ACHN cell line was transfected with miR-200b/c 
(+) and 96 hours later growth inhibition was assessed by SRB assay following treatment with increasing doses of rapamycin. **p < 0.01; 
***p < 0.001; ****p < 0.0001. Experiments were performed three times in triplicates and a representative set of results is displayed. 
C. ACHN and MDA-MB-231 were transfected with ZEB1 siRNA and 72 hours later cells were harvested. EMT markers were assessed by 
western blotting. D. Following ZEB1 siRNA knockdown, ACHN cells were treated with increasing doses of rapamycin for 96 hours. Cell 
growth inhibition was assessed by SRB assay. ***p < 0.001; ****p < 0.0001. Experiments were performed three times in triplicates and a 
representative set of results is displayed.
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to that on the last day of treatment (Day 14). Percent 
change in tumor volume for all treatment groups were 
significantly less than control, but there was no difference 
in percent change in tumor volume between the mice 
treated with trametinib alone or with the combination of 
trametinib and rapamycin (Figure 6B). Notably western 
blotting for EMT markers did not demonstrate modulation 
of EMT with trametinib treatment despite inhibition of 
MAPK signaling (data not shown). Thus, trametinib 
caused tumor regression in MDA-MB-231 xenografts 
but did markedly modulate EMT nor did it further show 
antitumor efficacy in combination with rapamycin.
Given the differential response to EMT modulation 
with trametinib in vitro and the increased sensitivity to 
rapamycin observed with miR-200 transfection and ZEB1 
knockdown, we next sought to evaluate the effect of 
trametinib on EMT markers and rapamycin sensitivity in an 
ACHN xenograft model. Similar to our results for MDA-
MB-231 xenografts, trametinib caused tumor regression 
alone or in combination with rapamycin following 22-day 
treatment. However, the ACHN xenografts demonstrated 
greater tumor regression with trametinib in combination 
with rapamycin, whether trametinib was given prior to 
rapamycin treatment or simultaneously (Figure 6B). The 
percent change in tumor volume from Day 0 to Day 22 
of treatment demonstrated greater tumor regression with 
the combination of trametinib and rapamycin and a trend 
towards greater tumor regression with the pre-treatment 
trametinib combination group compared to simultaneous 
treatment (Figure 6B).
As trametinib not only modulates EMT, but also 
inhibits MAPK signaling, we further investigated the 
role of trametinib on cell growth on a MAPK-activated 
model. HMLER is an immortalized human mammary 
epithelial cell line (HMLE) transformed with V12H-Ras 
oncogene and rendered oncogenic [25, 26]. HMLER 
and HMLER-pWB (control vector) both had baseline 
activation of MAPK signaling. MAPK pathway signaling 
was further activated in HMLER-Snail and blocked 
with trametinib alone or in combination with rapamycin 
(Figure 6C). Trametinib alone inhibited both pathways but 
there was only a slight decrease in vimentin expression, 
not suggesting reverting EMT. Rapamycin was not able 
to block S6 phosphorylation completely. Of the markers 
examined, combination treatment did not result in more 
inhibition compared to trametinib alone. Tubulin was 
Figure 5: Vorinostat modulated EMT and showed synergistic effect with rapamycin in vitro but not in vivo. A. ACHN 
and MDA-MB-231 cells were treated with vorinostat 5 μM for 24, 48 or 72 hours. Western blotting was conducted to assess EMT markers 
E-cadherin and vimentin. B. ACHN and MDA-MB-231 cell lines were treated with rapamycin and vorinostat for 96 hours. Rapamycin and 
vorinostat combination drug ratios were 20:1, 40:1, and 80:1. The effect on cell growth was assessed by SRB assay, and combination index 
(CI) values were calculated. The graph represents the CI of rapamycin and vorinostat combination at ED50, ED75, and ED90. Range of CI: 
<0.9, synergism; 0.9–1.1, nearly additive; >1.1, antagonism. C. ACHN xenografts were treated with vehicle, rapamycin 1 mg/kg (Rapa 1), 
rapamycin 4 mg/kg (Rapa 4), vorinostat 80 mg/kg, combination rapamycin 1 mg/kg and vorinostat 80 mg/kg (Vori/Rapa 1) or rapamycin 
4 mg/kg and vorinostat 80 mg/kg (Vori/Rapa 4) for 19 days. MDA-MB-231 xenografts were treated with vehicle, rapamycin 1 mg/kg, 
vorinostat 80 mg/kg, or a combination of rapamycin and vorinostat (Rapa/Vori) at the same doses for 38 days.
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Figure 6: Trametinib modulated EMT in ACHN and increased sensitivity of ACHN to lower doses of rapamycin.  
A. ACHN (left) and MDA-MB-231 (right) were treated daily with DMSO 0.1% (D), rapamycin 10 nM (R10), rapamycin 100 nM (R100), 
trametinib 10 μM (T), or in combination with each rapamycin dose (T+R10, T+R100) for 3 days and harvested for western blotting 24 hours 
later to assess EMT, MAPK and mTOR signaling. B. ACHN xenografts were treated with DMSO/Vehicle (Vehicle), rapamycin 1 mg/kg /
vehicle (Rapamycin), DMSO/trametinib 0.3 mg/kg (Trametinib), rapamycin/trametinib (Rapa/Tram) at the same doses, or trametinib daily 
for three days then followed by rapamycin/trametinib (Del Rapa/Tram) at the same doses daily for a total of 14 days. *p < 0.05, **p < 0.01. 
MDA-MB-231 xenografts were treated with DMSO/Vehicle (Vehicle), rapamycin 1 mg/kg /vehicle (Rapamycin), DMSO/trametinib 
0.3 mg/kg (Trametinib), or rapamycin/trametinib (Rapa/Tram) at the same doses daily for 14 days. *p < 0.05, **p < 0.01, ****p < 0.0001.  
C. HMLER, HMLER-pWB, and HMLER-Snail cell lines were treated daily with DMSO 0.1%, rapamycin 100 nM (R), trametinib 10 μM 
(T), or rapamycin and trametinib combination (R+T) with the same doses for 3 days. Cells were harvested for western blotting 24 hours 
after the last treatment and assessed for EMT, MAPK and mTOR signaling. D. HMLER (parenteral), HMLER-pWB (control vector), and 
HMLER-Snail were treated with various doses of rapamycin (R), trametinib (T) or their combination (R+T) for 4 days. Rapamycin:trametinib 
combination ratio was 1:1. Sensitivity to drugs was assessed by SRB assay. Results were normalized to DMSO control.
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also increased in HMLER-Snail cell line; consistent 
with previous reports that reorganization of cytoskeleton 
causes increase in actin and tubulin expression [27–29]. 
A similar increase was also observed in MEK, Erk, and 
Akt. We have treated HMLER (parenteral), HMLER-pWB 
(control vector), and HMLER-Snail cells with increasing 
doses rapamycin and trametinib alone and in combination 
(Figure 6D). Trametinib alone or in combination with 
rapamycin inhibited cell growth in all three panels at 
doses of 25 nM or higher. However, in HMLER-Snail 
model, reverting EMT did not provide more growth 
inhibition to combination with rapamycin compared to 
trametinib alone.
DISCUSSION
We found an association with EMT and rapamycin 
resistance on a functional proteomic screen. Further, we 
demonstrated that mesenchymal cell lines selected by 
an EMT signature are more resistant to rapamycin. We 
thus hypothesized that the mesenchymal status of cancer 
cells, exhibited through absence of E-cadherin expression 
and presence of vimentin expression, correlated with 
resistance to rapamycin both in vitro and in mouse 
xenografts. However, some, but not all mechanisms of 
EMT modulation resulted in increased sensitivity to 
rapamycin in cancer cell lines in vitro and in vivo.
The rapamycin analog temsirolimus is approved 
by the Food and Drug Administration for the treatment 
of advanced renal cell carcinoma, and the rapamycin 
analog everolimus is FDA-approved for the treatment of 
pancreatic neuroendocrine tumors, renal cell carcinoma, 
sub-ependymal giant cell astrocytoma associated with 
tuberous sclerosis, and hormone-receptor positive breast 
cancer (in combination with exemestane). There has been 
intensive study on mechanism of action and mechanisms 
of intrinsic sensitivity and resistance to rapamycin, but 
largely, biomarkers predictive for response to rapalogs 
have not been identified. Although both somatic TSC1 
mutation [30] and mTOR mutations [31] have been 
reported in exceptional responders, these alterations are 
relatively rare in tumor types such as hormone–receptor 
positive breast cancer and neuroendocrine tumors, where 
rapalogs are commonly used. In preclinical studies 
PIK3CA/PTEN mutations were associated with rapalog 
sensitivity [19], but to date PIK3CA mutations have 
not been confirmed to predict response to rapalogs in 
clinical trials [32]. It is also worth noting that rapalogs 
are associated with toxicities, including stomatitis of 
mild- to moderate severity including, pneumonitis, and 
hyperglycemia [33]. Although these side effects are 
usually manageable, they highlight the need to identify 
biomarkers of response to spare patients who will not 
benefit from these agents these side effects.
There were differences in expression and 
phosphorylation of MAPK and Akt/mTOR pathway 
markers in MCF7 Snail-WT and Snail-6SA cell lines. 
Rapamycin was reported to activate MAPK pathway 
through S6K-PI3K-Ras feedback loop in various models 
[34, 35]. MAPK activation accompanied with incomplete 
inhibition of S6 phosphorylation and Akt activation 
indicated resistance to rapamycin, and provided rationale 
for a combination of MAPK and mTOR inhibitors in 
treatment of cancer.
EMT has been associated with chemoresistance to 
several chemotherapeutic agents including paclitaxel [36], 
oxaliplatin [37], gemcitabine [38], 5-fluororacil [39] 
as well as targeted therapies such as tamoxifen [40], 
erlotinib and PI3K/Akt inhibitors [21]. RNA-based 
multiplex predictors such as Oncotype Dx Recurrence 
Score and MammaPrint have been effectively transitioned 
to clinical use; thus, it would be important to determine 
whether a RNA- or protein-based predictor can indeed 
have predictive utility. In our study, cell lines that were 
classified as mesenchymal based on two EMT signatures 
were less sensitive to rapamycin; although sensitivity to 
everolimus and temsirolimus was less, this difference 
did not reach statistical significance. It is worthy of note 
that in contrast to our in vitro findings, metaplastic breast 
cancer, a mesenchymal tumor type, has previously been 
reported to be especially responsive to a temsirolimus 
containing therapy regimen; 42% objective response 
rate was reported for temsirolimus, bevacizumab and 
liposomal doxorubicin [41]. Whether this sensitivity is 
attributable to sensitivity to temsirolimus or bevacizumab 
and liposomal doxorubicin remains unclear. Thus, further 
study is needed to determine whether EMT correlates with 
clinical resistance (early progression or lack of clinical 
benefit) to rapalogs as single agent as well in combination 
therapy.
A variety of preclinical approaches has been 
proposed to reverse EMT. In our experiments, in 
each mechanism of EMT modulation in vitro, ACHN 
demonstrated increased E-cadherin expression and 
increased sensitivity to rapamycin. In addition, vorinostat 
and trametinib treatments induced E-cadherin expression. 
However, in vivo neither of the drugs increased E-cadherin 
expression, and rapamycin and vorinostat combination had 
no effect on tumor growth. Thus, in vitro findings were 
not capitulated with in vivo results. Notably our results 
differ than those reported in epidermoid squamous cell 
carcinoma xenografts, where vorinostat both reversed 
EMT and inhibited tumor growth [24]. In addition to 
differences in cell lines used to establish the xenografts, 
at least one difference may be that in our model we started 
treatment after tumors were established (mean volume ± 
SEM, 118 ± 15 mm3) whereas the other model introduced 
an early treatment protocol that started on day 3 [24]. 
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However, we feel treatment of established tumors better 
models treatment of patients with advanced disease in 
early phase clinical trials.
We observed an increase in E-cadherin expression 
in MDA-MB-231 by miR200b/c transfection and ZEB1 
knockdown, however, there was no growth inhibition. 
MDA-MB-231 has BRAF and RAS mutations that may 
render MDA-MB-231 resistant to rapamycin regardless 
of EMT status. This was further supported by our 
findings with HMLER cell line, and in the presence of 
RAS mutation, reverting EMT by trametinib treatment 
did not induce sensitivity to rapamycin. In ACHN cell 
line, E-cadherin was increased after miR200b/c or 
ZEB1 transfections and trametinib treatment, which may 
have been adequate to alter EMT and its crosstalk with 
PI3K/mTOR signaling, ultimately to result in increased 
sensitivity to rapamycin. Simultaneous targeting of Ras/
Raf/MEK/Erk and PI3K/Akt/mTOR pathways has already 
been proposed as an approach to overcome resistance 
to Raf-i or MEK inhibitors [42, 43]. In both MDA-
MB-231 and ACHN cell lines, trametinib alone or in 
combination with rapamycin was better than rapamycin 
alone, but we were unable to demonstrate reversion of 
EMT in these models. In HMLER cell lines, trametinib 
alone or in combination with rapamycin inhibited growth 
more than rapamycin alone. There was a decrease in 
vimentin expression but we did not capture an increase 
in E-cadherin expression and we were not able to 
demonstrate reversion of EMT clearly. We did not capture 
an increase in p-S6K (data not shown), which is upstream 
S6. Although p-S6 was increased in HMLER-Snail cell 
line, probably PI3K pathway was not activated but rather 
MEK/Erk/p90RSK axis phosphorylated S6. Trametinib 
alone was able to inhibit activity of both MAPK and 
PI3K/mTOR pathways. Our finding raises the possibility 
that trametinib’s synergy with rapamycin may be through 
mechanisms independent of MET.
Future studies are needed to determine optimal 
agents for reversion of EMT modulation and to determine 
the effect of combinations of these agents with PI3K/Akt/
mTOR inhibitors.
MATERIALS AND METHODS
Cell lines and culture
ACHN, BT-474, BT-483, MCF7, MDA-MB-231, 
MDA-MB-453, and ZR75–1 cell lines were obtained from 
the American Type Culture Collection. MDA-MB-435 
and NCI/ADR-RES cells were obtained from the National 
Cancer Institute. Cell lines were passaged for less than six 
months following resuscitation, and thus were not tested 
for characterization. ATCC utilizes Short Tandem Repeat 
(STR) profiling to verify cell line identity. Cells were 
cultured in DMEM/F12 supplemented with 10% fetal 
bovine serum at 37°C and humidified 5% CO2. MCF7 cell 
lines containing Snail-WT, Snail-2SA or Snail-6SA were 
created as previously described [23] and grown in DMEM/
F12 supplemented with 10% fetal bovine serum and 
G418 400 μg/ml. HMLER (parenteral), HMLER-pWB 
(control vector) and HMLER-Snail cells were cultured in 
DMEM/F12:MEGM (with BPE supplement) (1:1) media 
supplemented with hEGF 5 ng/ml, hydrocortisone 0.25 
μg/ml, insulin 2.5 μg/ml, and blasticidin 4 μg/ml.
Reagents
Rapamycin and vorinostat were purchased from 
LC Laboratories, Inc. Trametinib was purchased from 
Selleck Chemicals. For in vivo experiments, 0.5% 
hydroxypropylmethylcellulose (Sigma) and 0.2% 
Tween-80 (Sigma) in distilled water (pH 8.0) was used 
as oral gavage vehicle as previously described [17]. 
DMSO (vehicle for rapamycin for in vitro and in vivo 
experiments), polyethylene glycol (vehicle for vorinostat 
for in vivo experiments), and G418 were purchased from 
Sigma.
Western blotting
Cells were washed with cold PBS and lysed in 
100 mM Tris-HCl (pH 6.8), 4% SDS, and 20% glycerol, 
and then protein were separated by SDS-PAGE. The 
protein was transferred to a 0.2 μm nitrocellulose 
membrane (Bio-Rad Laboratories). Membranes were 
blocked with 0.1% casein in TBS. Immunoblotting was 
performed with the following antibodies: caveolin-1, 
pan-cytokeratin, E-cadherin, Erk 1/2, p-Erk 1/2 (Thr202/
Tyr204), MEK1/2, p-MEK1/2 (S217/221), p-S6 
(Ser240/244), p-S6 (Ser235/236), S6, p-Akt T308, p-Akt 
S473, Akt, p90RSK S380, α-tubulin (Cell Signaling 
Technology), fibronectin, ERα, smad3 (Epitomics), Snail, 
vimentin (Abcam), actin (Sigma), and ZEB1 (Bethyl). 
The immunoblots were visualized using the Odyssey IR 
imaging system and software (Li-Cor Biosciences).
Reverse phase protein arrays
Reverse phase protein array (RPPA) was performed 
at the MD Anderson Cancer Center Functional Proteomics 
RPPA Core Facility as described previously [44–46], 
and specifically represents cells and samples with two 
biological replicates prepared as previously described [19]. 
Protein levels were presented as log2 of mean expression 
values.
Small interfering RNA
The silencing of ZEB1 with small interfering 
RNA (siRNA) was performed using DharmaFECT 1 
transfection reagent and siGENOME SMARTpool 
Human ZEB1 siRNA (GAACCACCCUUGAAAGUGA, 
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GAAGCAGGAUGUACAGUAA, AAACUGAACCUGU 
GGAUUA, GAUAGCACUUGUCUUCUGU) or 
siGENOME Non-targeting siRNA Pool #2 (Dharmacon). 
Cells were harvested after 72 hours and lysates obtained 
for western blotting or trypsinized and plated for growth 
assay experiments.
MicroRNA




and miR-200c (CCCUCGUCUUACCCAGCAGUGUUU 
GGGUGCGGUUGGGAGUCUCUAAUACUGCCGGG 
UAAUGAUGGAGG) in a 50:50 ratio or Negative Control 
miRNA #1 was performed using reverse transfection 
method and siPORT NeoFX transfection reagent 
(Ambion). Cells were harvested after 72 hours and lysates 
obtained for western blotting or trypsinized and plated for 
growth assay experiments.
Growth assays
For rapamycin antiproliferative activity, cells were 
plated in triplicate in 96-well plates at densities of 500 to 
5, 000 cells per well depending on growth characteristics 
of each cell line. Cell growth was measured at 5 days 
(baseline rapamycin sensitivity classification) and 
4 days (miR-200 transfection and ZEB1 knockdown) 
using sulforhodamine B (SRB) assay as previously 
described [47]. The median inhibitory concentration (IC50) 
and combination index (CI) were determined from dose-
response curves as previously described [48]. Cells were 
categorized as rapamycin sensitive (RS) or rapamycin 
resistant (RR) based on IC50 cutoff value of 100 nM.
In vivo studies
All animal studies were conducted according to the 
guidelines of the American Association of Laboratory 
Animal Care under a protocol approved by the MD 
Anderson Animal Care and Use Committee. ACHN 
(6.67 × 106) and MDA-MB-231 (1 × 107) cells, mixed 
with Matrigel (BD Biosciences), were inoculated into the 
mammary fat pads of six-week-old female athymic nude 
(nu/nu) mice (Department of Experimental Radiation 
Oncology, MD Anderson). In trametinib-rapamycin study, 
after tumors formed, MDA-MB-231 xenografts were 
randomized into 4 groups (DMSO intraperitoneal injection 
(IP) weekly/oral gavage vehicle daily, DMSO IP weekly/
trametinib 0.3 mg/kg body weight oral gavage daily, 
rapamycin 1 mg/kg IP weekly/oral gavage vehicle daily, 
or rapamycin 1 mg/kg IP weekly/trametinib 0.3 mg/kg 
body weight oral gavage daily, n = 7–8). After tumors 
formed, ACHN xenografts were randomized into 5 groups 
(DMSO IP weekly/oral gavage vehicle daily, DMSO IP 
weekly/trametinib 0.3 mg/kg body weight oral gavage 
daily, rapamycin 1 mg/kg IP weekly/oral gavage vehicle 
daily, rapamycin 1 mg/kg IP weekly/trametinib 0.3 mg/kg 
body weight oral gavage daily, or trametinib 0.3 mg/kg 
body weight oral gavage daily for three days followed by 
simultaneous rapamycin 1 mg/kg IP weekly/trametinib 
0.3 mg/kg body weight oral gavage daily n = 8). In 
vorinostat-rapamycin study, after tumors formed, MDA-
MB-231 xenografts were randomized into 4 groups 
(vehicle 10% DMSO-PEG:water IP three times per 
week, rapamycin 1 mg/kg IP weekly, vorinostat 80 mg/kg 
IP three times per week, rapamycin 1 mg/kg IP weekly/
vorinostat 80 mg/kg IP three times per week, n = 5). After 
tumors formed, ACHN xenografts were randomized into 
6 groups (vehicle 10% DMSO-PEG:water IP three times per 
week, rapamycin 1 mg/kg IP weekly, rapamycin 4 mg/kg 
IP weekly, vorinostat 80 mg/kg IP three times per week, 
rapamycin 1 mg/kg IP weekly/vorinostat 80 mg/kg IP three 
times per week, rapamycin 4 mg/kg IP weekly/vorinostat 
80 mg/kg IP three times per week, n = 8). The tumor 
growth was followed by caliper measurements and tumor 
volumes were calculated as previously described [49]. 
Mice were euthanized 24 hours after the last treatment, 
and half of each tumor was snap-frozen while the other 
half was fixed in formalin and embedded in paraffin.
Statistical analysis
The cell line RPPA slide data was analyzed for 
differences in expression between RS and RR cell lines 
using linear mixed effects model with fixed effect of 
sensitivity and time point, and random effect of cell 
line. To account for multiple testing, we estimated 
the false discovery rates (FDR) of the F-tests of the 
cell line sensitivity effect using beta-uniform mixture 
model. All results shown in bar graphs and line graphs 
are presented as means ± SE. Growth inhibition (SRB 
data) of MCF7 Snail-WT v. MCF7 Snail-6SA following 
rapamycin treatment was compared with a Student’s 
t-test. Growth inhibition with rapamycin (SRB data) 
for miR-200 transfection and ZEB1 knockdown was 
compared to respective control using 2-Way ANOVA for 
treatment v. rapamycin/DMSO followed by Bonferroni 
multiple comparison tests. For trametinib-rapamycin and 
vorinostat-rapamycin in vivo experiments, tumor volume 
at the last day and percent change in tumor volume from 
day 0 to the last day were both compared among all 
treatment groups by 1-way ANOVA followed by Tukey 
multiple comparison test or Kruskal Wallis test followed 
by Dunn’s multiple comparison test. All statistical tests 
used a significance level of 5%.
For the analysis of association between breast 
cancer cell line sensitivity and EMT signature, we defined 
the cell line sensitivity by using the average of GI50 values 
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on Log10 scale of all cell lines available in GI50 data from 
Daemen et al. for rapamycin, everolimus or temsirolimus 
respectively [20]. We extracted the gene expression 
information from data from Daemen et al. that matches 
Byers and Gröger EMT signature genes for the cell lines 
with GI50 and sensitivity information for the compounds 
of interest. For the Byers EMT signature, probe set ID 
was used as the identifier. There are 48 probe sets in 
Daemens’s Affymetrix U133A data mapping to Byers’ 97 
probe sets signature from Affymetrix U133plus2 data. For 
Gröger’s signature, gene symbol was used as identifier 
and multiple probe sets for the same gene symbols were 
extracted when available. We conducted similar analysis 
for Byers’ and Gröger’s EMT signatures on the probe set 
level. Two-way hierarchical clustering was conducted to 
cluster Affymetrix probe sets corresponding to the EMT 
signature genes using Pearson correlation distance metric 
and cluster cell lines using Euclidean distance metric with 
the Ward’s linkage rule. The cell lines were grouped into 
epithelial (green bar) and mesenchymal (red bar) groups 
at the first major branching of the dendrogram. Wilcoxon 
rank sum tests were used to compare the Log10GI50 values 
between epithelial and mesenchymal cell lines.
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